AiCuris Promising Drugs against Herpes Simplex and Human Cytomegalovirus in Preparation for Phase III

AiCuris will present at the International Herpesvirus Workshop in Calgary, Canada, on its two front-running compounds targeting herpes viruses.

AiCuris will present at the International Herpesvirus Workshop in Calgary, Canada, on its two front-running compounds targeting herpes viruses, on August 8th 2012 at 2 pm, in the plenary session on interventions.

AIC316 and Letermovir (AIC246) have successfully completed double-blinded, placebo-controlled phase II dose-ranging trials, meeting the primary and secondary study endpoints with excellent and dose-proportional efficacy and a good safety profile. Both compounds can be administered orally once daily for prophylaxis and suppression of the virus. The long halflife of AIC316, in addition, likely allows dosing only one pill per herpes episode.

AIC316 and Letermovir are non-nucleosidic drugs and act via a novel mode of